April 15, 2024 —Neumora Therapeutics, a biopharmaceutical firm listed on Nasdaq as NMRA, has encountered a setback in its clinical trials.

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921.

April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE.

April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.

TransCode Therapeutics, an RNA oncology company, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1/2 clinical trial for its lead therapeutic candidate, TTX-MC138.

April 15, 2024 — ORIC Pharmaceuticals, a clinical-stage oncology company, has completed the dose escalation phase of its Phase 1b trial for ORIC-114.

Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.

May 15th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Novo Nordisk A/S reports that in the Frontier 2 study, their once-weekly and once-monthly Mim8 treatments significantly outperformed standard and prior prophylaxis treatments in reducing bleeding episodes in individuals with haemophilia A.

Mabwell reported progress in its clinical trial of the novel Nectin-4 targeting ADC (9MW2821) for triple-negative breast cancer treatment.

AC Immune and Takeda Enter an Exclusive Deal for Licence and Option on Active Immunotherapy Focused on Amyloid Beta for Alzheimer's Disease.

Kodiak Sciences has started treating initial participants in the Phase 3 GLOW2 study, examining Tarcocimab Tedromer for diabetic retinopathy.